Pretreatment values of bilirubin and albumin are not prognostic predictors in patients with advanced pancreatic cancer.
Lanyun Feng,Shihui Gu,Peng Wang,Hao Chen,Zhen Chen,Zhiqiang Meng,Luming Liu
DOI: https://doi.org/10.1002/cam4.1848
IF: 4.711
2018-01-01
Cancer Medicine
Abstract:Purpose To identify the pretreatment values of bilirubin and albumin and other serum biomarkers in predicting the prognosis for advanced pancreatic cancer. Methods A total of 201 consecutive patients pathologically diagnosed as advanced pancreatic cancer were retrospectively reviewed. Tumor location, TNM classification, the level of baseline total bilirubin (TBIT), direct bilirubin (DBIT), albumin (ALB), globulin (GLOB), total protein (TP), ALB to GLOB ratio (AGR), CA19-9, CA242, and CA50 were collected. The values of CA19-9, CA242, and CA50 were divided into two groups according to the upper limit value which were 1000 U/mL, 150 IU/mL, and 500 IU/mL, respectively. The values of TBIL, DBIL, IBIL, ALB, GLOB, TP, ALB, and GLOB were divided into low and high groups according to the median. To investigate if the median was an effective discriminator in dividing these markers, the patients were divided into a test set (n = 100) and a validation set (n = 101). Kaplan-Meier (K-M) survival analysis and Cox regression analysis were performed to explore the potential relationship between them and overall survival (OS). Results A K-M survival analysis revealed that the investigated markers in test set, including TBIL, DBIL, IBIL, ALB, GLOB, TP, ALB, and GLOB, were not associated with the OS. The findings from the validation set were consistent with those in the test set. Factors with P value smaller than 0.1 in the univariate analysis along with the tumor location, CA19-9, CA242, CA50, were entered into the multivariate analysis. A Cox regression analysis suggested that the cancerization at head of pancreas (P = 0.01) and a high level of CA19-9 (P = 0.02) were independent prognostic indicators for poor OS of pancreatic cancer. Conclusions Baseline bilirubin and serum proteins were not associated with the prognosis of advanced pancreatic cancer. Tumor location and level of CA19-9 may serve as significant indicators for poor prognosis in those patients.